Exelixis (EXEL)
(Delayed Data from NSDQ)
$26.97 USD
-0.20 (-0.74%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $26.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Price, Consensus and EPS Surprise
EXEL 26.97 -0.20(-0.74%)
Will EXEL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EXEL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EXEL
Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel Revenues
Exelixis (EXEL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
EXEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings
Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Tops Revenue Estimates
Other News for EXEL
Biotech Alert: Searches spiking for these stocks today
Exelixis: Balancing Strong Financials with Operational Challenges in Berens’s Hold Rating
Exelixis Comes Up Aces
Analysts’ Top Healthcare Picks: Pliant Therapeutics (PLRX), Exelixis (EXEL)
Exelixis’s Strong Financials and Drug Development Promise Buoy Buy Rating and Raised Price Target